[go: up one dir, main page]

HK1212905A1 - 用於防止登革熱病毒感染的疫苗組合物 - Google Patents

用於防止登革熱病毒感染的疫苗組合物

Info

Publication number
HK1212905A1
HK1212905A1 HK16100914.5A HK16100914A HK1212905A1 HK 1212905 A1 HK1212905 A1 HK 1212905A1 HK 16100914 A HK16100914 A HK 16100914A HK 1212905 A1 HK1212905 A1 HK 1212905A1
Authority
HK
Hong Kong
Prior art keywords
virus infection
dengue virus
vaccine compositions
prevention against
against dengue
Prior art date
Application number
HK16100914.5A
Other languages
English (en)
Inventor
Jiansheng Yao
Yves Girerd-Chambaz
Isabelle Legastelois
Nathalie Mantel
Vronique Barban
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of HK1212905A1 publication Critical patent/HK1212905A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16100914.5A 2012-07-24 2016-01-28 用於防止登革熱病毒感染的疫苗組合物 HK1212905A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305911 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (1)

Publication Number Publication Date
HK1212905A1 true HK1212905A1 (zh) 2016-06-24

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100914.5A HK1212905A1 (zh) 2012-07-24 2016-01-28 用於防止登革熱病毒感染的疫苗組合物

Country Status (15)

Country Link
US (1) US20150265695A1 (zh)
EP (1) EP2877207A1 (zh)
JP (1) JP2015524422A (zh)
KR (1) KR20150036593A (zh)
CN (1) CN104812408A (zh)
AU (1) AU2013295016A1 (zh)
BR (1) BR112015001313A2 (zh)
CA (1) CA2878599A1 (zh)
GT (1) GT201500005A (zh)
HK (1) HK1212905A1 (zh)
MX (1) MX2015000446A (zh)
PE (1) PE20150356A1 (zh)
PH (1) PH12014502875A1 (zh)
SG (1) SG11201500439RA (zh)
WO (1) WO2014016362A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211814A1 (es) 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
EP3010536A4 (en) * 2013-06-21 2016-11-30 Merck Sharp & Dohme DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
PH12017501165B1 (en) * 2014-12-22 2023-02-22 Merck Sharp & Dohme Llc Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
SI3355915T1 (sl) * 2015-09-29 2024-03-29 Boehringer Ingelheim Animal Health USA Inc. Cepiva z virusu podobnim delcem (vlp) pasjega parvovirusa (cpv) in njihove uporabe
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
JP4504464B2 (ja) 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
AU4040200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
MXPA02001177A (es) * 1999-08-02 2002-07-02 Wyeth Corp Recuperacion del virus de las paperas del acido desoxirribonucleico recombinante.
JP4656794B2 (ja) 2000-02-16 2011-03-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー 無毒性の免疫原性フラビウイルスキメラ
ES2315221T3 (es) 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
BR0210907A (pt) * 2001-06-01 2004-12-21 Acambis Inc Vetores de flavivìrus quiméricos
WO2003010197A2 (en) 2001-07-25 2003-02-06 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
ES2677348T3 (es) * 2002-05-03 2018-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Un virus del dengue quimérico recombinante rDEN3/4delta 30(ME), rDEN2/4delta30(ME) o rDEN1/4delta30(ME) que contiene una deleción de 30 nucleótidos (delta30) en una sección de la región no traducida en 3' del genoma del dengue de tipo 4, en donde dicha deleción de 30 nucleótidos se corresponde con la estructura tallo-bucle de TL2
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CN102010463A (zh) * 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
JP5075120B2 (ja) * 2005-06-17 2012-11-14 サノフィ・パスツール デング熱セロタイプ２の弱毒化株
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8591916B2 (en) * 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2461822A4 (en) * 2009-07-29 2013-07-17 Bernd Helmut Adam Rehm POLYMER PARTICLES AND APPLICATIONS THEREOF
US8900596B2 (en) * 2009-11-18 2014-12-02 The Board Of Regents Of The University Of Texas System Physicochemical (PCP) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
EP2571990A4 (en) * 2010-05-21 2013-11-20 Univ Pittsburgh UNIVERSAL SEQUENCES OF DENGUE VIRUS AND METHODS OF USE
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
MY197723A (en) * 2012-07-24 2023-07-10 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection

Also Published As

Publication number Publication date
PH12014502875A1 (en) 2015-02-23
BR112015001313A2 (pt) 2017-08-01
WO2014016362A1 (en) 2014-01-30
US20150265695A1 (en) 2015-09-24
EP2877207A1 (en) 2015-06-03
SG11201500439RA (en) 2015-02-27
CN104812408A (zh) 2015-07-29
PE20150356A1 (es) 2015-03-20
KR20150036593A (ko) 2015-04-07
CA2878599A1 (en) 2014-01-30
MX2015000446A (es) 2015-03-12
AU2013295016A1 (en) 2015-01-29
GT201500005A (es) 2015-10-13
JP2015524422A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
HK1212905A1 (zh) 用於防止登革熱病毒感染的疫苗組合物
HK1214962A1 (zh) 流感病毒免疫原性組合物及其應用
HK1209646A1 (zh) 經鼻流感疫苗組合物
HK1212906A1 (zh) 疫苗組合物
IL229307A0 (en) Inactivated dengue virus vaccine
PL2647387T3 (pl) Kompozycja szczepionki
PT2806891T (pt) Vacinas baseadas no vírus parainfluenza 5
EP2825196A4 (en) ADJUVANT AND VACCINE COMPOSITIONS
PL2935313T3 (pl) Szczepionki przeciwko wirusowi zapalenia wątroby typu b
HK1206986A1 (zh) 流行性感冒病毒感染癥的預防‧治療劑
IL237431A0 (en) Immunogenic preparations
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
SG11201502221WA (en) Novel attenuated dengue virus strains for vaccine application
IL236476A0 (en) Preparations and methods for the treatment or prevention of infection with the pneumovirus and diseases related to it
SG11201510617WA (en) Methods and compositions for dengue virus vaccines
FR2992161B1 (fr) Protection intra-buccale
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
PL2852614T3 (pl) Szczepionka oparta na składniku dopełniacza - C5A
HK1209140A1 (zh) 牛流感病毒組合物
HK1201283A1 (zh) 丙型流感病毒和疫苗
HK1209647A1 (zh) 針對登革病毒的疫苗組合物
GB201215184D0 (en) Therapeutic virus
AU2013369626A1 (en) Dengue virus vaccine composition
AU2012905097A0 (en) Agents and methods for inhibiting virus infection
EP2897548A4 (en) INCISION PROTECTION